FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322769730> ?p ?o ?g. }

• W4322769730 endingPage "492" @default.
• W4322769730 startingPage "492" @default.
• W4322769730 abstract "Background and Objectives: Opioid analgesics, which are used for cancer-related pain management, cause opioid-induced constipation (OIC). Naldemedine, a peripheral opioid receptor antagonist, is an OIC-modifying agent, but no focused efficacy and safety analysis has been conducted for its use in hepatobiliary pancreatic cancers. We performed a multi-institutional study on the efficacy and safety of naldemedine in patients with hepatobiliary pancreatic cancer using opioids in clinical practice. Materials and Methods: We retrospectively evaluated patients with hepatobiliary pancreatic cancer (including liver, biliary tract, and pancreatic cancers) treated with opioids and naldemedine during hospitalization at ten institutions in Japan from June 2017 to August 2019. We assessed the frequency of bowel movements before and after the initiation of naldemedine therapy. Responders were defined as patients who defecated ≥3 times/week, with an increase from a baseline of ≥1 defecations/week over seven days after the initiation of naldemedine administration. Results: Thirty-four patients were observed for one week before and one week after starting naldemedine. The frequency of bowel movements increased by one over the baseline frequency or to at least thrice per week in 21 patients. The response rate was 61.7% (95% confidence interval: 45.4-78.0%). The median number of weekly bowel movements before and after naldemedine treatment was 2 (range: 0-9) and 6 (range: 1-17), respectively, in the overall population (n = 34); the increase in the number of bowel movements following naldemedine administration was statistically significant (Wilcoxon signed-rank test, p < 0.0001). Diarrhea was the predominant gastrointestinal symptom, and 10 (29.4%) patients experienced grade 1, grade 2, or grade 3 adverse events. The only other adverse event included fatigue in one patient; grade 2-4 adverse events were absent. Conclusions: Naldemedine is effective, and its use may be safe in clinical practice for patients with hepatobiliary pancreatic cancer receiving opioid analgesics." @default.
• W4322769730 created "2023-03-03" @default.
• W4322769730 creator A5007410117 @default.
• W4322769730 creator A5010025596 @default.
• W4322769730 creator A5024707759 @default.
• W4322769730 creator A5031415039 @default.
• W4322769730 creator A5033780369 @default.
• W4322769730 creator A5035023922 @default.
• W4322769730 creator A5036450127 @default.
• W4322769730 creator A5037351215 @default.
• W4322769730 creator A5042535005 @default.
• W4322769730 creator A5046262423 @default.
• W4322769730 creator A5052817269 @default.
• W4322769730 creator A5068337381 @default.
• W4322769730 creator A5069932697 @default.
• W4322769730 creator A5070441398 @default.
• W4322769730 creator A5083169678 @default.
• W4322769730 creator A5085372925 @default.
• W4322769730 creator A5087890566 @default.
• W4322769730 date "2023-03-02" @default.
• W4322769730 modified "2023-09-23" @default.
• W4322769730 title "A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer" @default.
• W4322769730 cites W1576185322 @default.
• W4322769730 cites W1917158670 @default.
• W4322769730 cites W2011518853 @default.
• W4322769730 cites W2040109649 @default.
• W4322769730 cites W2070697890 @default.
• W4322769730 cites W2072575748 @default.
• W4322769730 cites W2103456710 @default.
• W4322769730 cites W2156266538 @default.
• W4322769730 cites W2159762136 @default.
• W4322769730 cites W2164448950 @default.
• W4322769730 cites W2167582502 @default.
• W4322769730 cites W2176756126 @default.
• W4322769730 cites W2271853934 @default.
• W4322769730 cites W2337387091 @default.
• W4322769730 cites W2416156024 @default.
• W4322769730 cites W2563316401 @default.
• W4322769730 cites W2592597011 @default.
• W4322769730 cites W2608589775 @default.
• W4322769730 cites W2763722121 @default.
• W4322769730 cites W2769448136 @default.
• W4322769730 cites W2801854693 @default.
• W4322769730 cites W2803067490 @default.
• W4322769730 cites W2834719472 @default.
• W4322769730 cites W2889122884 @default.
• W4322769730 cites W2889646458 @default.
• W4322769730 cites W2895428615 @default.
• W4322769730 cites W2942443205 @default.
• W4322769730 cites W2952389281 @default.
• W4322769730 cites W2952622458 @default.
• W4322769730 cites W2953617862 @default.
• W4322769730 cites W2966347491 @default.
• W4322769730 cites W3008544558 @default.
• W4322769730 cites W3132304675 @default.
• W4322769730 cites W3213614815 @default.
• W4322769730 cites W4211073917 @default.
• W4322769730 cites W4211155124 @default.
• W4322769730 cites W4211181525 @default.
• W4322769730 cites W4211183069 @default.
• W4322769730 cites W4229449634 @default.
• W4322769730 cites W4284702018 @default.
• W4322769730 doi "https://doi.org/10.3390/medicina59030492" @default.
• W4322769730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36984494" @default.
• W4322769730 hasPublicationYear "2023" @default.
• W4322769730 type Work @default.
• W4322769730 citedByCount "0" @default.
• W4322769730 crossrefType "journal-article" @default.
• W4322769730 hasAuthorship W4322769730A5007410117 @default.
• W4322769730 hasAuthorship W4322769730A5010025596 @default.
• W4322769730 hasAuthorship W4322769730A5024707759 @default.
• W4322769730 hasAuthorship W4322769730A5031415039 @default.
• W4322769730 hasAuthorship W4322769730A5033780369 @default.
• W4322769730 hasAuthorship W4322769730A5035023922 @default.
• W4322769730 hasAuthorship W4322769730A5036450127 @default.
• W4322769730 hasAuthorship W4322769730A5037351215 @default.
• W4322769730 hasAuthorship W4322769730A5042535005 @default.
• W4322769730 hasAuthorship W4322769730A5046262423 @default.
• W4322769730 hasAuthorship W4322769730A5052817269 @default.
• W4322769730 hasAuthorship W4322769730A5068337381 @default.
• W4322769730 hasAuthorship W4322769730A5069932697 @default.
• W4322769730 hasAuthorship W4322769730A5070441398 @default.
• W4322769730 hasAuthorship W4322769730A5083169678 @default.
• W4322769730 hasAuthorship W4322769730A5085372925 @default.
• W4322769730 hasAuthorship W4322769730A5087890566 @default.
• W4322769730 hasBestOaLocation W43227697301 @default.
• W4322769730 hasConcept C121608353 @default.
• W4322769730 hasConcept C126322002 @default.
• W4322769730 hasConcept C170493617 @default.
• W4322769730 hasConcept C2777498785 @default.
• W4322769730 hasConcept C2779802037 @default.
• W4322769730 hasConcept C2780210213 @default.
• W4322769730 hasConcept C2781063702 @default.
• W4322769730 hasConcept C2781112942 @default.
• W4322769730 hasConcept C2908647359 @default.
• W4322769730 hasConcept C71924100 @default.
• W4322769730 hasConcept C90924648 @default.
• W4322769730 hasConcept C99454951 @default.

• next